anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Biodistribution (Within the Body) and Vector Shedding (Excretion/Secretion)

BEQVEZ vector DNA levels were measured and quantified in blood and various shedding matrices using a quantitative polymerase chain reaction (qPCR) assay. This assay is sensitive and specific to BEQVEZ vector DNA, but could also detect DNA fragments. Saliva, semen, and urine samples from a subset of patients in the clinical study 1 were further characterized by measuring encapsidated vector DNA by a modified assay.

Nonclinical Biodistribution

Biodistribution of BEQVEZ was evaluated approximately 92 days after intravenous administration in healthy male non-human primates (NHPs) at dose levels up to 5 × 1012 vg/kg. Vector DNA was detected in all tissues assessed, including the testes. The highest levels of vector DNA were detected in the liver, spleen, and inguinal lymph nodes.

Clinical Data

Vector shedding after infusion with BEQVEZ was assessed in 60 patients at multiple time points in clinical studies (clinical study 1 and clinical study 2). In clinical study 1 a subset of patients (n=17) provided optional samples at early timepoints (2, 24 and 72 hours post-infusion) to better define parameters such as maximum vector DNA level (Cmax) and time to maximum vector DNA level (Tmax). The maximum vector DNA concentrations were found in plasma followed by saliva, peripheral blood mononuclear cells (PBMC), semen and urine. The mean Tmax was 1.2 days for plasma and saliva and 1.6 days for urine. The mean Tmax was 3.8 days and 7.4 days for semen and PBMC, respectively. For pooled analysis of clinical data (N=60 patients), full clearance of vector DNA was defined as having 3 consecutive negative results (i.e., below quantification limit). Vector DNA fully cleared from plasma, saliva, and semen within a mean of 1 to 4 months after infusion and PBMC was the slowest fluid to full clearance within a mean of 12 months. In semen, the maximum observed time for vector DNA full clearance was 154 days. In urine, the peak vector DNA concentration was very low relative to plasma and declined to full clearance within a mean of 4 weeks after infusion.
For the control arm, participants will receive the same 30-minute Body Project class, then participants will be given a 30-minute nutrition education lesson. The nutrition lesson plans will have no components of self-compassion intertwined within the lesson, but the nutrition content will be the same as the treatment group.
Atherosclerosis, a chronic inflammatory disorder, leads to cardio-cerebrovascular diseases, causing most of the global deaths. The chronic and non-resolved inflammatory responses of both innate and adaptive immune cells are involved in the all-stage pathogenesis of atherosclerosis. The impairment of inflammatory resolution promotes atherogenesis and causes instability of atherosclerotic plaques. Their subsequent rupture would induce severe cardio-cerebrovascular incidences (e.g., acute myocardial infarction and ischemic strokes). Recent progress in anti-inflammatory immunotherapies on human atherosclerosis opens the door to resolving this inflammatory disorder by targeting the immune system. However, the impacts of PD-1 immune checkpoint blockades on the progressions of human carotid plaques are not determined yet.

This is a prospective cohort study, which aims to evaluate the effectiveness of PD-1 immune checkpoint blockades on atherosclerotic carotid plaques in tumor patients in comparison to those with non-PD-1-treated tumor patients. The method for quantification and evaluation of atherosclerotic plaques are based on: (1) the mean intima-media thickness of the common carotid artery (Mean CCA thickness); (2) the maximum intima-media thickness of the internal carotid artery (maximum ICA thickness); (3) Carotid plaque areas: by calculation of the plaque area of atherosclerotic plaques on the long axis direction of artery on the ultrasound images. By comparing the above-mentioned parameters at the same location of the carotid artery in the patients when initiating the first dose of anti-PD-1 or non-PD-1 chemotherapy and 3 months after anti-PD-1 or non-PD-1 chemotherapy. It is designed to assess the effectiveness of PD-1 immune checkpoint blockades or non-PD-1 chemotherapy on the clinical prognosis of carotid plaques after a period of 3-month treatment.
FIELD: laser therapy. SUBSTANCE: mucous coat of respiratory tract is exposed to laser irradiation for which purpose aerosol inhalation is performed. Aerosol is irradiated by laser beam which is directed according to inhaled air flow. Use is made of laser provided with flask which has light reflecting internal surface. Radiator and inhalation mouthpiece are positioned coaxially on flask ends, and internal space of flask communicates with aerosol delivery device. EFFECT: higher results of treatment. 3 cl, 2 dwg
BACKGROUND: Pulmonary rehabilitation (PR) is a programme of exercise and education and the most effective treatment for the symptoms and disability associated with chronic obstructive pulmonary disease. However, the benefits of PR are limited by poor uptake and completion. This trial will determine whether using trained volunteer lay health workers, called "PR buddies," improves uptake and completion of PR and is cost-effective. This trial protocol outlines the methods for evaluating effectiveness, cost-effectiveness, and acceptability.
METHODS: The IMPROVE trial is a pragmatic, open, cluster randomised controlled trial planned in 38 PR services across England and Wales. PR services will be randomised to either intervention arm-offering support from PR buddies to patients with chronic obstructive pulmonary disease-or to usual care as the control arm. PR staff in trial sites randomised to the intervention arm will receive training in recruiting and training PR buddies. They will deliver training to volunteers, recruited from among people who have recently completed PR in their service. The 3-day PR-buddy training programme covers communication skills, confidentiality, boundaries of the PR-buddy role and behaviour change techniques to help patients overcome obstacles to attending PR. An internal pilot will test the implementation of the trial in eight sites (four intervention sites and four in control arm). The primary outcome of the trial is the uptake and completion of PR. A process evaluation will investigate the acceptability of the intervention to patients, PR staff and the volunteer PR buddies, and intervention fidelity. We will also conduct a cost-effectiveness analysis.
DISCUSSION: Improving outcomes for chronic obstructive pulmonary disease and access to PR are priorities for the UK National Health Service (NHS) in its long-term plan. The trial hypothesis is that volunteer PR buddies, who are recruited and trained by local PR teams, are an effective and cost-effective way to improve the uptake and completion rates of PR. The trial is pragmatic, since it will test whether the intervention can be incorporated into NHS PR services. Information obtained in this trial may be used to influence policy on the use of PR buddies in PR and other similar services in the NHS.
TRIAL REGISTRATION: ISRCTN12658458. Registered on 23/01/2023.
Children undergoing heart surgery are under significant bodily stress, which can lead to higher than normal or lower than normal blood glucose levels. A synthetic form of insulin, a naturally occurring hormone in the body, can be injected into people to normalize blood glucose levels. Insulin is most commonly used to treat people with diabetes, but it is also used in hospitals to control blood glucose levels in patients. Previous studies of adult intensive care unit (ICU) patients have shown that patients whose blood sugar levels are maintained at normal levels with the use of insulin contract fewer infections and are released more quickly from the ICU than patients who do not maintain normal blood glucose levels. This study will use a continuous blood glucose monitoring system to detect changes in blood glucose levels. Intravenous insulin infusions will be used to then safely maintain normal blood glucose levels. The purpose of this study is to determine if maintaining normal blood glucose levels during an ICU stay will help decrease the incidence of infections and improve surgical recovery in young children following heart surgery.

This study will enroll children who are undergoing heart surgery that requires a cardiopulmonary bypass procedure. Participants will be randomly assigned to either a control group or the treatment group. All participants will receive usual care while in the ICU and will undergo continuous glucose monitoring. Participants in the treatment group will receive intravenous insulin infusions to keep their blood glucose within the normal range. While in the ICU, blood will be collected from all participants once a day for the first 3 days and then once a week to monitor glucose levels, hormone levels, and measurements of nutrition and immune function. On days 1 and 5 following surgery, participants who are on a ventilator will have their breath measured to monitor heart function and energy use. Thirty days and 1 year following surgery, study researchers will contact the participant's parent or doctor to collect information on health status and any new infections at the surgical site. Children who enroll in the study will be asked to participate in follow-up neurodevelopmental evaluations at 1 and 3 years of age to assess longer term cognitive effects of tight glycemic control in the ICU.
The utility model relates to the technical field of a medical plaster for disease treatment, and discloses an allergic rhinitis medical plaster which aims at solving the technical problems that when tThe utility model relates to the medial plaster treating disease technical field and discloses a plaster for allergic rhinitis. The utility model aims to solve the technical problem of the poor effecthe existing treatment methods for allergic rhinitis, such as oral administration medicine treatment or drop treatment is carried out, the existing treatment methods for allergic rhinitis has the disad or the drug addiction existing in the therapeutic methods for allergic rhinitis in the prior art such as orally taken medicines or dripping medicines. The technical proposal of the utility model inclvantages of poor treatment effect and drug dependence. The utility model adopts the technical proposal that the allergic rhinitis medical plaster adopts the principle of acupuncture point and meridianudes the therapy based on the plaster on the acupoints and the principle of human meridians, wherein the plaster comprises a back liner as the base layer of the plaster, wherein the back liner is adhe medicine application and comprises a back lining layer, wherein the back lining layer is the base layer of the medical plaster and is pasted with an impermeable layer on which a medicine adhesive layred with an anti-leakage layer adhered with a medicine glue layer which is in turn adhered with a protective layer. The utility model mainly used to treat allergic rhinitis has the advantages of rapider is pasted, and a protective layer is attached to the medicine adhesive layer. The utility model is mainly used for treating the allergic rhinitis, and has the advantages of obvious effect, slow rel effect, controlled release, long duration of effect, safe and convenient use, etc.                                                                                                                     ease, long-term effect, safety, convenient use, etc.
A 12-month double-blind, randomized, parallel group, placebo-controlled multicenter study was conducted in the U.S. and Canada to evaluate the efficacy and safety of estradiol 10 mcg in the treatment of atrophic vaginitis in 309 postmenopausal women between 46 and 81 years of age (mean 57.6 years of age) who at baseline identified their most bothersome symptom of atrophic vaginitis from among six symptoms (vaginal dryness, vaginal and/or vulvar irritation/itching, vaginal soreness, dysuria, dyspareunia and vaginal bleeding associated with intercourse). Women inserted one insert intravaginally each day for 14 days, then one insert twice weekly for the remaining 50 weeks. The majority (92.9 percent) of the women were Caucasian (n=287), 3.2 percent were Black (n=10), 1.6 percent were Asian (n=5) and 2.2 percent were Other (n=7). All participants were assessed for improvement in the mean change from baseline to Week 12 for co-primary efficacy variables of: a composite of most bothersome symptoms of atrophic vaginitis; percentage of vaginal superficial cells and percentage of vaginal parabasal cells on a vaginal smear; and vaginal pH. 

Relief of Vaginal Symptoms 

Estradiol 10 mcg was statistically superior to placebo in reducing the severity of a composite score of most bothersome symptoms associated with atrophic vaginitis at Week 12 (see Table 3).

Also demonstrated for estradiol 10 mcg compared to placebo was a statistically significant increase in the percentage of superficial cells at Week 12 (13.2 percent compared to 3.8 percent for matching placebo, p<0.001), a statistically significant decrease in parabasal cells at Week 12 (-37 percent compared to -9.3 percent for matching placebo, p<0.001), and a statistically significant mean reduction between baseline and Week 12 in vaginal pH score (-1.3 compared to -0.4 for matching placebo, p<0.001).

Endometrial safety was assessed by endometrial biopsy at the screening and final study visit. Of the 172 women in the estradiol 10 mcg group who had a biopsy performed at end of study, 92 women had endometrial tissue that was atrophic or inactive and 73 women had no tissue or tissue insufficient for diagnosis. There was one case of adenocarcinoma grade 2 and one case of complex hyperplasia without atypia. Three women exhibited polyps (two atrophic polyps and one adenomyomatus type polyp) and two others had adenomyosis and an atypical epithelial proliferation. 

Endometrial safety of estradiol 10 mcg was additionally evaluated in a second, 12 month, open-label, multicenter safety study. Of the 297 women who had a biopsy performed at end of study, 183 women had endometrial tissue that was atrophic or inactive and 111 women had no tissue or tissue insufficient for diagnosis. There was one case of complex hyperplasia without atypia. Two women exhibited polyps.
Participant's AKs in facial skin or scalp are first clinically graded and demarcated in two symmetric treatment areas on different sides of face. The areas will be curettaged thinly and next a SPF20 sun protection cream is applied on all sun-exposed areas of the skin. Then a 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid) gel is applied on one treatment side and MAL (methyl 5-aminolevulinate) cream on the other side. The sides will be randomized and the participant doesn't know which side is treated with which light sensitizer. After appropriate absorption time of 30 minutes the patients will be taken to the hospital balcony or yard for 2 hour illumination with natural daylight to accomplish the phototoxic reaction. Maximum dosage of light sensitizer will be 2 grams.
BACKGROUND: Moyamoya disease (MMD) is considered a progressive disease with an ongoing risk of recurrent stroke. However, there is a lack of long-term observational data to quantify the extent of the stroke risk.
METHODS: This study aimed to provide insight into the long-term stroke risk in MMD and explore possible risk factors for stroke. Records from all patients diagnosed with MMD in 13 clinical departments from 6 different Danish hospitals between 1994 and 2017 were retrospectively reviewed until 2021.
RESULTS: The cohort comprised 50 patients (33 females and 17 males). Patients were followed up for a median of 9.4 years, with more than 10 years of follow-up for 24 patients. Ten patients had 11 new stroke events-6 ischemic strokes and 5 brain hemorrhages. Events occurred at a median of 7 years and up to 25 years after diagnosis. The overall Kaplan-Meier 5-year stroke risk was 10%. Patients with bypass performed had significantly fewer events than conservatively treated patients (HR 0.25, 95% confidence interval (CI) 0.07-0.91, p < 0.05). All but one event occurred in females, a difference that reached statistical significance.
CONCLUSIONS: The study provides data on the extent of the risk of recurrent stroke in MMD. Bypass surgery patients had fewer stroke events than those treated conservatively. There was a trend toward a higher stroke risk in females.
DATA ACCESS STATEMENT: The data supporting this study's findings are available from the corresponding author upon reasonable request.
The following adverse reactions were identified during post-approval use of candesartan cilexetil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. 

The following have been very rarely reported in post-marketing experience: Digestive: Abnormal hepatic function and hepatitis. Hematologic: Neutropenia, leukopenia, and agranulocytosis. Immunologic:Angioedema. Metabolic and Nutritional Disorders: Hyperkalemia, hyponatremia.Respiratory System Disorders:Cough. Skin and Appendages Disorders: Pruritus, rash and urticaria.Rare reports of rhabdomyolysis have been reported in patients receiving angiotensin II receptor blockers
Frailty stands out as a particularly challenging multidimensional geriatric syndrome in the elderly population, often resulting in diminished quality of life and heightened mortality risk. Negative consequences encompass a heightened likelihood of hospitalization and institutionalization, as well as suboptimal post-hospitalization outcomes and elevated mortality rates. Using a questionnaire-based approach for assessing frailty has been shown to be an effective method for early diagnosis of frailty. Nonetheless, the majority of current frailty assessment tools necessitate in-person consultations. This poses a significant challenge for elderly patients residing in rural areas, who often encounter difficulties in accessing healthcare compared to their urban or suburban counterparts. Additionally, elderly patients face an elevated risk of contracting diseases as a result of frequent hospital visits, given that many of them are immunocompromised. An automated initial frailty assessment approach can help mitigate the challenges mentioned above and conserve clinical resources by circumventing the need for extensive manual assessments. The primary aim of this paper is to introduce an automatic initial frailty assessment method. This method efficiently identifies individuals who may necessitate further frailty evaluation by automatically extracting relevant information from a patient's clinical notes and using it to complete the Tillburg Frailty Indicator (TFI) questionnaire. The introduced phrase-based query expansion technique is designed to identify the most pertinent phrases related to the frailty assessment questionnaire using Unified Medical Language System (UMLS) ontology and incorporates information from clinical notes to enhance its accuracy. Additionally, a method for retrieving pertinent clinical notes to automatically facilitate the frailty assessment process based on the identified phrases was also proposed. The proposed approaches are evaluated using a dataset containing a collection of clinical notes from elderly patients, assessing their effectiveness in terms of automating frailty assessment and question-answering tasks. This research underscores the significance of incorporating phrases as features in the automated frailty assessment process using clinical notes. The research empowers clinicians to conduct automatic frailty assessments utilizing medical data, thereby reducing the need for frequent hospital visits and in-patient consultations. This becomes particularly valuable during unusual or unexpected situations, such as the COVID-19 pandemic, where minimizing in-person interactions is crucial.
For oral use only.

The use of BUPHENYL Tablets is indicated for children weighing more than 20 kg and for adults.

The usual total daily dose of BUPHENYL Tablets and Powder for patients with urea cycle disorders is 450–600 mg/kg/day in patients weighing less than 20 kg, or 9.9–13.0 g/m2/day in larger patients. The tablets and powder are to be taken in ­equally divided amounts with each meal or feeding (i.e., three to six times per day).

BUPHENYL Powder is indicated for oral use (via mouth, gastrostomy, or nasogastric tube) only. The powder is to be mixed with food (solid or liquid) for immediate use; however, when dissolved in water, BUPHENYL Powder has been shown to be stable for up to one week at room temperature or refrigerated. Sodium phenylbutyrate is very soluble in water (5 grams per 10 mL). When BUPHENYL Powder is added to a liquid, only sodium phenylbutyrate will dissolve, the excipients will not. The effect of food on sodium phenylbutyrate has not been determined. 

Each level teaspoon (enclosed) dispenses 3.2 grams of powder and 3.0 grams of sodium phenylbutyrate. Each level tablespoon (enclosed) dispenses 9.1 grams of powder and 8.6 grams of sodium phenylbutyrate.

Shake lightly before use.

The safety or efficacy of doses in excess of 20 grams (40 tablets) per day has not been established.
High-pressure bleeding wounds (and other bleeding wounds) may be treated by applying direct pressure directly in the bleeding wound, such as by applying a back pressure in a confined space around and in the wound. Certain substances and articles may be inserted into the wound, and the wound may be enclosed with that substance or article (such as a hemostatic substance, which may be polymeric), by swelling on contact with molecules (such as water molecules in the blood) encountered in the wound, generates the desired pressure to stop or at least reduce the bleeding without the detrimental effects of a tourniquet. Clot-inducing substances may be introduced into the wound contemporaneously with direct pressure application directly in the wound. Compressible and non-compressible wounds are treated. Treatment stops bleeding without producing pressure injury or ischemic damage. Medical devices using this technology are provided, including removable, biodegradable, medic-administrable devices.
Despite antiretroviral therapy (ART), HIV persists in latently-infected cells (the HIV reservoir) which decay slowly over time. Here, leveraging >500 longitudinal samples from 67 people living with HIV (PLWH) treated during acute infection, we developed a mathematical model to predict reservoir decay from peripheral CD4 + T cells. Nonlinear generalized additive models demonstrated rapid biphasic decay of intact DNA (week 0-5: t1/2 ~ 2.83 weeks; week 5-24: t1/2 ~ 15.4 weeks) that extended out to 1 year. These estimates were ~5-fold faster than prior decay estimates among chronic treated PLWH. Defective DNA had a similar biphasic pattern, but data were more variable. Predicted intact and defective decay rates were faster for PLWH with earlier timing of ART initiation, higher initial CD4 + T cell count, and lower pre-ART viral load. In this study, we advanced our limited understanding of HIV reservoir decay at the time of ART initiation, informing future curative strategies targeting this critical time.